2025/05/28 by Hiba Abbas, Maria Kokosi, Nishanth Sivarasan
Biochemistry, Genetics and Molecular Biology · Medicine · #Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis #S100 Proteins and Annexins #Sarcoidosis and Beryllium Toxicity Research
paper · doi:10.1093/bjr/tqaf118
crossref issued 2025/05/28 · crossref published 2025/05/28 · crossref published-online 2025/05/28 · openalex publication_date 2025/05/28 · crossref created 2025/05/28 · crossref published-print 2025/08/01 · crossref deposited 2025/08/12 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31 · crossref indexed 2026/07/31
Pulmonary sarcoidosis, although generally associated with a good prognosis, remains challenging to manage in view of its unpredictable disease behaviour and outcome. Being able to phenotype patients with sarcoidosis could potentially facilitate treatment decisions and promote research anchored to disease behaviour and outcome. Efforts to phenotype sarcoidosis using imaging date back to the early 1900s when chest X-rays were the main modality for lung parenchymal evaluation. However, despite significant advances in technology, there is currently no consensus on how we should classify this disease utilizing more modern imaging techniques. In this review, we provide an overview of imaging phenotypes in sarcoidosis, discuss the challenges of disease classification, evaluate associations between imaging appearance and outcome, and explore new developments in this field.